-
Mashup Score: 5Cardiovascular Manifestations and Management in ADPKD - 6 month(s) ago
Cardiovascular disease (CVD) is the major cause of mortality in autosomal dominant polycystic kidney disease (ADPKD) and contributes to significant bu…
Source: www.sciencedirect.comCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 0Walk for PKD | PKD Foundation - 7 month(s) ago
About The Walk for PKD is the largest fundraising event for polycystic kidney disease (PKD), raising over $35 million since the year 2000. At the event, the PKD Foundation brings together patients, physicians, and researchers to strengthen the community for all impacted by PKD. When you ask your friends and family to support you and the Walk for PKD, 100% of each donation will fund life-saving…
Source: walkforpkd.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Homocysteine Metabolism and Endothelial Function in ADPKD - 7 month(s) ago
Learn more about services at Mayo Clinic.
Source: www.mayo.eduCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
Glycosphingolipids are a class of membrane lipids that regulate numerous cellular processes, including membrane organization, proliferation, cell cycle regulation, apoptosis, transport, migration, and inflammatory signaling.1 Dysregulation of this critical pathway in polycystic kidney disease (PKD) was first reported several decades ago. In the cpk/cpk mouse model, which exhibits renal pathology similar to human autosomal recessive PKD, levels of glucosylceramide (GL-1) and lactosylceramide were greater, ceramide levels were higher, and glucosylceramide synthase (GCS) activity was elevated as compared to control kidneys, suggesting the sphingolipids may play a role in disease progression (Fig 1).
Source: www.ajkd.orgCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 3Treatment Options for Autosomal Dominant Polycystic Kidney Disease (ADPKD): What Works and What Does Not - 9 month(s) ago
Alissar El Chediak @alissar_chediak Dr. Alissar El Chediak is currently a transplant nephrology fellow at Vanderbilt University Medical Center. She was born and raised in Lebanon where she attended…
Source: AJKD BlogCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 0Treatment Options for Autosomal Dominant Polycystic Kidney Disease (ADPKD): What Works and What Does Not - 9 month(s) ago
Alissar El Chediak @alissar_chediak Dr. Alissar El Chediak is currently a transplant nephrology fellow at Vanderbilt University Medical Center. She was born and raised in Lebanon where she attended…
Source: AJKD BlogCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 3
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease, according to the press release.“Orphan drug designation represents a major milestone for the company in pursuit of marketing approval for Xorlo, our proprietary formulation of oxypurinol, and the XRx-008 program for [autosomal dominant PKD]
Source: www.healio.comCategories: Latest Headlines, NephrologyTweet
-
Mashup Score: 0
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @KIReports: #Cardiovascular Manifestations and Management in #ADPKD https://t.co/DE4MZxkW1E #KIRReview https://t.co/cb55skB0HY